Search company, investor...

Alacrity Biosciences

alacritybio.com

Founded Year

2005

Stage

Debt | Alive

Total Raised

$8.7M

Last Raised

$250K | 11 yrs ago

About Alacrity Biosciences

Alacrity Biosciences is a biopharmaceutical company focused on acquiring, developing and commercializing therapeutics to treat ophthalmic diseases that threaten vision and reduce patient quality of life.

Headquarters Location

28335 Quiet Hill Lane

Trabuco Canyon, California, 92679,

United States

Missing: Alacrity Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Alacrity Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Alacrity Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Alacrity Biosciences is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Alacrity Biosciences Patents

Alacrity Biosciences has filed 1 patent.

The 3 most popular patent topics include:

  • Analog circuits
  • Capacitors
  • Electrophysiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/16/2020

5/24/2022

Membrane biology, Capacitors, Ion channels, Electrophysiology, Analog circuits

Grant

Application Date

3/16/2020

Grant Date

5/24/2022

Title

Related Topics

Membrane biology, Capacitors, Ion channels, Electrophysiology, Analog circuits

Status

Grant

Alacrity Biosciences Frequently Asked Questions (FAQ)

  • When was Alacrity Biosciences founded?

    Alacrity Biosciences was founded in 2005.

  • Where is Alacrity Biosciences's headquarters?

    Alacrity Biosciences's headquarters is located at 28335 Quiet Hill Lane, Trabuco Canyon.

  • What is Alacrity Biosciences's latest funding round?

    Alacrity Biosciences's latest funding round is Debt.

  • How much did Alacrity Biosciences raise?

    Alacrity Biosciences raised a total of $8.7M.

  • Who are the investors of Alacrity Biosciences?

    Investors of Alacrity Biosciences include ReGen Partners, Actin Biomed and Paramount BioSciences.

  • Who are Alacrity Biosciences's competitors?

    Competitors of Alacrity Biosciences include Vasopharm, TARIS Biomedical - LiRIS, Aursos, IASO Pharma, Lux Biosciences and 13 more.

Compare Alacrity Biosciences to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

I
Institute for OneWorld Health

A No-profit/no-loss Pharmaceutical Company Targeting Five Diseases In Need Of Drug Development. The company's First Drug, Paromomycin, Is A Treatment For Visceral Leishmaniasis Which Is An Illness Impacting The World's Poorest And Spread By Sand Flies. nnIt's Next Focus Is Malaria Where It Aims To Create And Market Semisynthetic Artemisinin. This Is A Key Malaria Battling Ingredient Which Is In Short Supply.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

C
Cosmo S.p.A.

Cosmo is a fully-integrated speciality pharmaceutical company that aims to become engaged in the market of optimised therapies for selected gastro-intestinal diseases. The company's clinical development pipeline specifically addresses treatments for Inflammatory Bowel Diseases (IBD), such as Ulcerative Colitis and Crohn's Disease, as well as for colon infections.

A
Antipodean

Antipodean is a pharmaceutical company developing treatments for neurodegenerative diseases such as Parkinson's Disease and Friedreich's Ataxia that are associated with mitochondrial dysfunction.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.